Advertisement
News
Advertisement

Pulmatrix makes $1.4M deal with cystic fibrosis group

Fri, 09/14/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Pulmatrix Inc. in Lexington is collaborating with the Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) in a deal worth up to $1.4 million to bring the biotech’s inhaled drug candidate, PUR118, to treat cystic fibrosis, through clinical trials.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading